http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 24 Feb 2026 16:10:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Veradigm+Inc.+++++++++++++For%3A+Feb+20/26051573.html si-local-file:///var/storage/secattach/20260224/26051573.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Veradigm+Inc.+++++++++++++For%3A+Feb+20/26051573.html Tue, 24 Feb 2026 16:10:00 -0500 MDRX O.00079869 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Veradigm+Inc.+++++++++++++For%3A+Feb+20/26051573.html si-local-file:///var/storage/secattach/20260224/26051573.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Veradigm+Inc.+++++++++++++For%3A+Feb+20/26051573.html Tue, 24 Feb 2026 16:10:00 -0500 MDRX O.00079869 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Veradigm+Inc.++++++++++++++++++++++++++Filed+by%3A+Silver+Point+Capital+L.P./26015189.html si-local-file:///var/storage/secattach/20260217/26015189.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Veradigm+Inc.++++++++++++++++++++++++++Filed+by%3A+Silver+Point+Capital+L.P./26015189.html Tue, 17 Feb 2026 17:20:00 -0500 MDRX O.00079869 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Veradigm+Inc.++++++++++++++++++++++++++Filed+by%3A+Silver+Point+Capital+L.P./26015189.html si-local-file:///var/storage/secattach/20260217/26015189.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Veradigm+Inc.++++++++++++++++++++++++++Filed+by%3A+Silver+Point+Capital+L.P./26015189.html Tue, 17 Feb 2026 17:20:00 -0500 MDRX O.00079869 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Veradigm+Inc.++++++++++++++++++++++++++Filed+by%3A+Two+Seas+Capital+LP/26013467.html si-local-file:///var/storage/secattach/20260217/26013467.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Veradigm+Inc.++++++++++++++++++++++++++Filed+by%3A+Two+Seas+Capital+LP/26013467.html Tue, 17 Feb 2026 16:23:00 -0500 MDRX O.00079869 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Veradigm+Inc.++++++++++++++++++++++++++Filed+by%3A+Two+Seas+Capital+LP/26013467.html si-local-file:///var/storage/secattach/20260217/26013467.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Veradigm+Inc.++++++++++++++++++++++++++Filed+by%3A+Two+Seas+Capital+LP/26013467.html Tue, 17 Feb 2026 16:23:00 -0500 MDRX O.00079869 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Veradigm+Inc.+++++++++++++For%3A+Feb+17/26012787.html si-local-file:///var/storage/secattach/20260217/26012787.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Veradigm+Inc.+++++++++++++For%3A+Feb+17/26012787.html Tue, 17 Feb 2026 16:11:00 -0500 MDRX O.00079869 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Veradigm+Inc.+++++++++++++For%3A+Feb+17/26012787.html si-local-file:///var/storage/secattach/20260217/26012787.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Veradigm+Inc.+++++++++++++For%3A+Feb+17/26012787.html Tue, 17 Feb 2026 16:11:00 -0500 MDRX O.00079869 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Veradigm+Inc.+++++++++++++For%3A+Feb+17/26012808.html si-local-file:///var/storage/secattach/20260217/26012808.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Veradigm+Inc.+++++++++++++For%3A+Feb+17/26012808.html Tue, 17 Feb 2026 16:11:00 -0500 MDRX O.00079869 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Veradigm+Inc.+++++++++++++For%3A+Feb+17/26012808.html si-local-file:///var/storage/secattach/20260217/26012808.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Veradigm+Inc.+++++++++++++For%3A+Feb+17/26012808.html Tue, 17 Feb 2026 16:11:00 -0500 MDRX O.00079869 http://www.streetinsider.com/Guidance/Veradigm+reports+flat+2025+revenue+amid+debt+restructuring+efforts/26012093.html <p>Veradigm Inc. (OTCMKTS: MDRX) reported preliminary fiscal 2025 revenue of $584 million to $589 million, representing a 1% decline from 2024's estimated range of $590 million to $595 million, according to a company statement.</p><p>The healthcare technology provider's cash position decreased significantly to $120 million as of December 31, 2025, compared to $294 million at the end of 2024. The $174 million reduction resulted primarily from debt refinancing activities, including repurchasing convertible notes for $229 million and borrowing $70 million under a new term loan facility.</p><p>Chief Executive Officer Donald Trigg outlined the company's strategic focus on what he termed a "Reset, http://www.streetinsider.com/Guidance/Veradigm+reports+flat+2025+revenue+amid+debt+restructuring+efforts/26012093.html Tue, 17 Feb 2026 16:01:48 -0500 MDRX http://www.streetinsider.com/Corporate+News/Veradigm+reports+flat+2025+revenue+amid+debt+restructuring+efforts/26012093.html <p>Veradigm Inc. (OTCMKTS: MDRX) reported preliminary fiscal 2025 revenue of $584 million to $589 million, representing a 1% decline from 2024's estimated range of $590 million to $595 million, according to a company statement.</p><p>The healthcare technology provider's cash position decreased significantly to $120 million as of December 31, 2025, compared to $294 million at the end of 2024. The $174 million reduction resulted primarily from debt refinancing activities, including repurchasing convertible notes for $229 million and borrowing $70 million under a new term loan facility.</p><p>Chief Executive Officer Donald Trigg outlined the company's strategic focus on what he termed a "Reset, http://www.streetinsider.com/Corporate+News/Veradigm+reports+flat+2025+revenue+amid+debt+restructuring+efforts/26012093.html Tue, 17 Feb 2026 16:01:48 -0500 MDRX http://www.streetinsider.com/Press+Releases/Veradigm+Provides+Business+and+Strategy+Update/26012034.html <p> CHICAGO--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.veradigm.com%2F&amp;esheet=54425056&amp;newsitemid=20260217785258&amp;lan=en-US&amp;anchor=Veradigm%26%23174%3B&amp;index=1&amp;md5=d566d2096fed84ba4d94604606e0e732" shape="rect">Veradigm®</a> (OTCMKTS: MDRX), a leading provider of clinical and revenue cycle solutions for independent practices, is providing estimated financial performance for the fiscal year 2025 and key areas of strategic focus for 2026. </p><p> “On my first investor call in October, I committed to advancing three strategic objectives in my first 100 days: reset our business strategy, recover our market leadership with independent physician practices and reignite profitable growth,” said Donald Trigg, CEO of Veradigm. “As we move through the first quarter, our ‘Reset, Recover, Reignite’ plan is launched. We have made progress http://www.streetinsider.com/Press+Releases/Veradigm+Provides+Business+and+Strategy+Update/26012034.html Tue, 17 Feb 2026 16:01:00 -0500 A.50213684 MDRX O.00049856 http://www.streetinsider.com/Press+Releases/Veradigm+Provides+Business+and+Strategy+Update/26012034.html <p> CHICAGO--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.veradigm.com%2F&amp;esheet=54425056&amp;newsitemid=20260217785258&amp;lan=en-US&amp;anchor=Veradigm%26%23174%3B&amp;index=1&amp;md5=d566d2096fed84ba4d94604606e0e732" shape="rect">Veradigm®</a> (OTCMKTS: MDRX), a leading provider of clinical and revenue cycle solutions for independent practices, is providing estimated financial performance for the fiscal year 2025 and key areas of strategic focus for 2026. </p><p> “On my first investor call in October, I committed to advancing three strategic objectives in my first 100 days: reset our business strategy, recover our market leadership with independent physician practices and reignite profitable growth,” said Donald Trigg, CEO of Veradigm. “As we move through the first quarter, our ‘Reset, Recover, Reignite’ plan is launched. We have made progress http://www.streetinsider.com/Press+Releases/Veradigm+Provides+Business+and+Strategy+Update/26012034.html Tue, 17 Feb 2026 16:01:00 -0500 A.50213684 MDRX O.00049856 http://www.streetinsider.com/Press+Releases/Veradigm+Provides+Business+and+Strategy+Update/26012034.html <p> CHICAGO--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.veradigm.com%2F&amp;esheet=54425056&amp;newsitemid=20260217785258&amp;lan=en-US&amp;anchor=Veradigm%26%23174%3B&amp;index=1&amp;md5=d566d2096fed84ba4d94604606e0e732" shape="rect">Veradigm®</a> (OTCMKTS: MDRX), a leading provider of clinical and revenue cycle solutions for independent practices, is providing estimated financial performance for the fiscal year 2025 and key areas of strategic focus for 2026. </p><p> “On my first investor call in October, I committed to advancing three strategic objectives in my first 100 days: reset our business strategy, recover our market leadership with independent physician practices and reignite profitable growth,” said Donald Trigg, CEO of Veradigm. “As we move through the first quarter, our ‘Reset, Recover, Reignite’ plan is launched. We have made progress http://www.streetinsider.com/Press+Releases/Veradigm+Provides+Business+and+Strategy+Update/26012034.html Tue, 17 Feb 2026 16:01:00 -0500 A.50213684 MDRX O.00049856 http://www.streetinsider.com/Business+Wire/Veradigm+Provides+Business+and+Strategy+Update/26012034.html <p> CHICAGO--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.veradigm.com%2F&amp;esheet=54425056&amp;newsitemid=20260217785258&amp;lan=en-US&amp;anchor=Veradigm%26%23174%3B&amp;index=1&amp;md5=d566d2096fed84ba4d94604606e0e732" shape="rect">Veradigm®</a> (OTCMKTS: MDRX), a leading provider of clinical and revenue cycle solutions for independent practices, is providing estimated financial performance for the fiscal year 2025 and key areas of strategic focus for 2026. </p><p> “On my first investor call in October, I committed to advancing three strategic objectives in my first 100 days: reset our business strategy, recover our market leadership with independent physician practices and reignite profitable growth,” said Donald Trigg, CEO of Veradigm. “As we move through the first quarter, our ‘Reset, Recover, Reignite’ plan is launched. We have made progress http://www.streetinsider.com/Business+Wire/Veradigm+Provides+Business+and+Strategy+Update/26012034.html Tue, 17 Feb 2026 16:01:00 -0500 A.50213684 MDRX O.00049856 http://www.streetinsider.com/Business+Wire/Veradigm+Provides+Business+and+Strategy+Update/26012034.html <p> CHICAGO--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.veradigm.com%2F&amp;esheet=54425056&amp;newsitemid=20260217785258&amp;lan=en-US&amp;anchor=Veradigm%26%23174%3B&amp;index=1&amp;md5=d566d2096fed84ba4d94604606e0e732" shape="rect">Veradigm®</a> (OTCMKTS: MDRX), a leading provider of clinical and revenue cycle solutions for independent practices, is providing estimated financial performance for the fiscal year 2025 and key areas of strategic focus for 2026. </p><p> “On my first investor call in October, I committed to advancing three strategic objectives in my first 100 days: reset our business strategy, recover our market leadership with independent physician practices and reignite profitable growth,” said Donald Trigg, CEO of Veradigm. “As we move through the first quarter, our ‘Reset, Recover, Reignite’ plan is launched. We have made progress http://www.streetinsider.com/Business+Wire/Veradigm+Provides+Business+and+Strategy+Update/26012034.html Tue, 17 Feb 2026 16:01:00 -0500 A.50213684 MDRX O.00049856 http://www.streetinsider.com/Business+Wire/Veradigm+Provides+Business+and+Strategy+Update/26012034.html <p> CHICAGO--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.veradigm.com%2F&amp;esheet=54425056&amp;newsitemid=20260217785258&amp;lan=en-US&amp;anchor=Veradigm%26%23174%3B&amp;index=1&amp;md5=d566d2096fed84ba4d94604606e0e732" shape="rect">Veradigm®</a> (OTCMKTS: MDRX), a leading provider of clinical and revenue cycle solutions for independent practices, is providing estimated financial performance for the fiscal year 2025 and key areas of strategic focus for 2026. </p><p> “On my first investor call in October, I committed to advancing three strategic objectives in my first 100 days: reset our business strategy, recover our market leadership with independent physician practices and reignite profitable growth,” said Donald Trigg, CEO of Veradigm. “As we move through the first quarter, our ‘Reset, Recover, Reignite’ plan is launched. We have made progress http://www.streetinsider.com/Business+Wire/Veradigm+Provides+Business+and+Strategy+Update/26012034.html Tue, 17 Feb 2026 16:01:00 -0500 A.50213684 MDRX O.00049856 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Veradigm+Inc.++++++++++++++++++++++++++Filed+by%3A+TD+SECURITIES+%28USA%29+LLC/25998223.html si-local-file:///var/storage/secattach/20260213/25998223.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Veradigm+Inc.++++++++++++++++++++++++++Filed+by%3A+TD+SECURITIES+%28USA%29+LLC/25998223.html Fri, 13 Feb 2026 13:08:00 -0500 AL21 MDRX O.00079869 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Veradigm+Inc.++++++++++++++++++++++++++Filed+by%3A+TD+SECURITIES+%28USA%29+LLC/25998223.html si-local-file:///var/storage/secattach/20260213/25998223.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Veradigm+Inc.++++++++++++++++++++++++++Filed+by%3A+TD+SECURITIES+%28USA%29+LLC/25998223.html Fri, 13 Feb 2026 13:08:00 -0500 AL21 MDRX O.00079869 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Veradigm+Inc.++++++++++++++++++++++++++Filed+by%3A+TD+SECURITIES+%28USA%29+LLC/25998223.html si-local-file:///var/storage/secattach/20260213/25998223.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Veradigm+Inc.++++++++++++++++++++++++++Filed+by%3A+TD+SECURITIES+%28USA%29+LLC/25998223.html Fri, 13 Feb 2026 13:08:00 -0500 AL21 MDRX O.00079869 http://www.streetinsider.com/Press+Releases/Veradigm+Brings+Patient+Voice+to+Healthcare+Research+with+New+Real-World+Data+Survey+Solution/25995819.html <p> CHICAGO--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fveradigm.com%2F&amp;esheet=54424456&amp;newsitemid=20260213828695&amp;lan=en-US&amp;anchor=Veradigm&amp;index=1&amp;md5=0e8df6a3eb482e0cda733e35c13473f8" shape="rect">Veradigm</a> (OTCMKTS:MDRX), a leading provider of clinical and revenue cycle solutions for independent practices, today announced a new patient‑reported outcomes (PRO) survey capability that brings the patient voice directly into <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fveradigm.com%2Freal-world-evidence-services%2F&amp;esheet=54424456&amp;newsitemid=20260213828695&amp;lan=en-US&amp;anchor=real%26%238209%3Bworld+evidence&amp;index=2&amp;md5=6865722b1c0ce4f5c1095b93f1a8340b" shape="rect">real‑world evidence</a> generation. The new solution gives life sciences organizations timely, privacy‑preserving insights directly from patients, adding essential context to clinical and observational research. </p><p> Built on Veradigm’s <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fveradigm.com%2Ffollowmyhealth-patient-engagement-platform%2F&amp;esheet=54424456&amp;newsitemid=20260213828695&amp;lan=en-US&amp;anchor=FollowMyHealth&amp;index=3&amp;md5=e6658be6ab1b8c6a015fe2fbbaf09a57" shape="rect">FollowMyHealth</a> patient engagement platform, the capability enables individuals to securely share their experiences through an account they own and manage. Patients receive project‑specific invitations through trusted channels http://www.streetinsider.com/Press+Releases/Veradigm+Brings+Patient+Voice+to+Healthcare+Research+with+New+Real-World+Data+Survey+Solution/25995819.html Fri, 13 Feb 2026 08:01:00 -0500 A.50213684 MDRX O.00049856 http://www.streetinsider.com/Press+Releases/Veradigm+Brings+Patient+Voice+to+Healthcare+Research+with+New+Real-World+Data+Survey+Solution/25995819.html <p> CHICAGO--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fveradigm.com%2F&amp;esheet=54424456&amp;newsitemid=20260213828695&amp;lan=en-US&amp;anchor=Veradigm&amp;index=1&amp;md5=0e8df6a3eb482e0cda733e35c13473f8" shape="rect">Veradigm</a> (OTCMKTS:MDRX), a leading provider of clinical and revenue cycle solutions for independent practices, today announced a new patient‑reported outcomes (PRO) survey capability that brings the patient voice directly into <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fveradigm.com%2Freal-world-evidence-services%2F&amp;esheet=54424456&amp;newsitemid=20260213828695&amp;lan=en-US&amp;anchor=real%26%238209%3Bworld+evidence&amp;index=2&amp;md5=6865722b1c0ce4f5c1095b93f1a8340b" shape="rect">real‑world evidence</a> generation. The new solution gives life sciences organizations timely, privacy‑preserving insights directly from patients, adding essential context to clinical and observational research. </p><p> Built on Veradigm’s <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fveradigm.com%2Ffollowmyhealth-patient-engagement-platform%2F&amp;esheet=54424456&amp;newsitemid=20260213828695&amp;lan=en-US&amp;anchor=FollowMyHealth&amp;index=3&amp;md5=e6658be6ab1b8c6a015fe2fbbaf09a57" shape="rect">FollowMyHealth</a> patient engagement platform, the capability enables individuals to securely share their experiences through an account they own and manage. Patients receive project‑specific invitations through trusted channels http://www.streetinsider.com/Press+Releases/Veradigm+Brings+Patient+Voice+to+Healthcare+Research+with+New+Real-World+Data+Survey+Solution/25995819.html Fri, 13 Feb 2026 08:01:00 -0500 A.50213684 MDRX O.00049856 http://www.streetinsider.com/Press+Releases/Veradigm+Brings+Patient+Voice+to+Healthcare+Research+with+New+Real-World+Data+Survey+Solution/25995819.html <p> CHICAGO--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fveradigm.com%2F&amp;esheet=54424456&amp;newsitemid=20260213828695&amp;lan=en-US&amp;anchor=Veradigm&amp;index=1&amp;md5=0e8df6a3eb482e0cda733e35c13473f8" shape="rect">Veradigm</a> (OTCMKTS:MDRX), a leading provider of clinical and revenue cycle solutions for independent practices, today announced a new patient‑reported outcomes (PRO) survey capability that brings the patient voice directly into <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fveradigm.com%2Freal-world-evidence-services%2F&amp;esheet=54424456&amp;newsitemid=20260213828695&amp;lan=en-US&amp;anchor=real%26%238209%3Bworld+evidence&amp;index=2&amp;md5=6865722b1c0ce4f5c1095b93f1a8340b" shape="rect">real‑world evidence</a> generation. The new solution gives life sciences organizations timely, privacy‑preserving insights directly from patients, adding essential context to clinical and observational research. </p><p> Built on Veradigm’s <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fveradigm.com%2Ffollowmyhealth-patient-engagement-platform%2F&amp;esheet=54424456&amp;newsitemid=20260213828695&amp;lan=en-US&amp;anchor=FollowMyHealth&amp;index=3&amp;md5=e6658be6ab1b8c6a015fe2fbbaf09a57" shape="rect">FollowMyHealth</a> patient engagement platform, the capability enables individuals to securely share their experiences through an account they own and manage. Patients receive project‑specific invitations through trusted channels http://www.streetinsider.com/Press+Releases/Veradigm+Brings+Patient+Voice+to+Healthcare+Research+with+New+Real-World+Data+Survey+Solution/25995819.html Fri, 13 Feb 2026 08:01:00 -0500 A.50213684 MDRX O.00049856 http://www.streetinsider.com/Business+Wire/Veradigm+Brings+Patient+Voice+to+Healthcare+Research+with+New+Real-World+Data+Survey+Solution/25995819.html <p> CHICAGO--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fveradigm.com%2F&amp;esheet=54424456&amp;newsitemid=20260213828695&amp;lan=en-US&amp;anchor=Veradigm&amp;index=1&amp;md5=0e8df6a3eb482e0cda733e35c13473f8" shape="rect">Veradigm</a> (OTCMKTS:MDRX), a leading provider of clinical and revenue cycle solutions for independent practices, today announced a new patient‑reported outcomes (PRO) survey capability that brings the patient voice directly into <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fveradigm.com%2Freal-world-evidence-services%2F&amp;esheet=54424456&amp;newsitemid=20260213828695&amp;lan=en-US&amp;anchor=real%26%238209%3Bworld+evidence&amp;index=2&amp;md5=6865722b1c0ce4f5c1095b93f1a8340b" shape="rect">real‑world evidence</a> generation. The new solution gives life sciences organizations timely, privacy‑preserving insights directly from patients, adding essential context to clinical and observational research. </p><p> Built on Veradigm’s <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fveradigm.com%2Ffollowmyhealth-patient-engagement-platform%2F&amp;esheet=54424456&amp;newsitemid=20260213828695&amp;lan=en-US&amp;anchor=FollowMyHealth&amp;index=3&amp;md5=e6658be6ab1b8c6a015fe2fbbaf09a57" shape="rect">FollowMyHealth</a> patient engagement platform, the capability enables individuals to securely share their experiences through an account they own and manage. Patients receive project‑specific invitations through trusted channels http://www.streetinsider.com/Business+Wire/Veradigm+Brings+Patient+Voice+to+Healthcare+Research+with+New+Real-World+Data+Survey+Solution/25995819.html Fri, 13 Feb 2026 08:01:00 -0500 A.50213684 MDRX O.00049856